Volver al Panel








AbbVie Inc. (ABBV)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
ABBV Intraday
No data available
SímboloABBV
Fecha de SalidaJan 2, 2013
CEOMr. Scott T. Reents
Empleados a Tiempo Completo57k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -0.53% | -1.40 US$ |
| 5 Días | -0.09% | -0.24 US$ |
| 1 Mes | +0.31% | +0.82 US$ |
| 6 Meses | +25.94% | +54.32 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de ABBV...
Estadísticas Clave
Cap. de Mercado
465.97B
Relación P/E
74.28
Rend. de Div.
2.61%
Máx. 52 Semanas
$269.39
Mín. 52 Semanas
$190.75
Consenso de Analistas
CONSENSOCompra
ALCISTA2480.0%
NEUTRAL516.7%
BAJISTA13.3%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$200.00
$200.00
Objetivo Máx.
$328.00
$328.00
Actual$263.71
Objetivo Prom.$278.61
Recomendaciones de Analistas
Precio Objetivo:$278.61($200.00 - $328.00)
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre ABBV
Únase a la comunidad para compartir su análisis
Últimas Noticias para ABBV

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
24/7 Wall St.•25 sept 2026, 15:01

ADARx Pharmaceuticals raises $446 million in upsized IPO
Quartz•25 sept 2026, 14:06

The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal•25 sept 2026, 09:30
ADARx Pharmaceuticals Prices Upsized $446.3 Million Initial Public Offering
MT Newswires•25 sept 2026, 08:27
RNAi drug specialist ADARx raises $446M IPO
BioPharma Dive•25 sept 2026, 00:36


AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Motley Fool•24 sept 2026, 21:19

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
Motley Fool•24 sept 2026, 20:22
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
GuruFocus.com•24 sept 2026, 19:39

Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Trefis•24 sept 2026, 19:03